Abstract
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Base Sequence
-
Cell Line, Tumor
-
Collagen / administration & dosage
-
Gene Transfer Techniques
-
Humans
-
Male
-
Mice
-
Mice, Nude
-
Molecular Sequence Data
-
Neovascularization, Pathologic / genetics
-
Neovascularization, Pathologic / therapy*
-
Prostatic Neoplasms / blood supply
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / therapy*
-
RNA, Small Interfering / administration & dosage
-
RNA, Small Interfering / genetics*
-
Transfection
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / biosynthesis
-
Vascular Endothelial Growth Factor A / genetics
-
Xenograft Model Antitumor Assays
Substances
-
RNA, Small Interfering
-
Vascular Endothelial Growth Factor A
-
atelocollagen
-
Collagen